TechNavio today launched its report Global Hyperphosphatemia Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; ”The Global Hyperphosphatemia Drugs market provides enough growth opportunity for vendors because of the increasing demand for phosphate binders in chronic kidney disease (CKD) and hyperphosphatemia treatments. Since iron-based phosphate binders have better phosphate-binding capacity, vendors in the market are investing heavily in R&D to develop iron-based phosphate binders for the treatment of hyperphosphatemia in end-stage renal disease patients.”
According to the report, there is an increase in the prevalence of CKD across the world, and CKD is one of the main causes of hyperphosphatemia. Thus, the increasing prevalence of kidney diseases will drive the Global Hyperphosphatemia Drugs market.
Further, the report also discusses that the biggest challenge that the Global Hyperphosphatemia Drugs market is facing is the side effects caused by currently used phosphate binders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit http://goo.gl/FODOK
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Report – Global Hyperphosphatemia Drugs Market 2011-2015
